Drug Discovery: from France to China Seminar
RMIT City Campus -
Thursday 15 December 2005-
Paul Vanhoutte M.D., Ph.D. is Distinguished Visiting Professor and Director of the Bio-Pharmaceutical Development Centre at the University of Hong Kong and President of the International Union of Pharmacology (IUPHAR).
Educated in Belgium, Paul subsequently held a variety of tenured positions at the University of Antwerp (1973-1981), the Mayo Clinic (1981-1989), and Baylor College of Medicine (1989-1995), and is extensively familiar with both American and European biomedical science. He then moved to an industry position serving (1995-2004) as the Vice President of Research and Development and Director of Discovery Research at the Institut de Recherches Servier. His research interests are in cardiovascular pharmacology and therapeutics, in particular, endothelium dependent relaxation, hyperpolarization, and contraction, and has a publication list that includes over 460 original research papers and almost as may additional reviews and book chapters.
Professor Paul Vanhoutte
Distinguished Visiting Professor
Director, Biopharmaceutical Development Centre
University of Hong Kong
Opening remarks by
H.E. François Descoueyte
Ambassador of France to Australia
Servier maintains a healthy product pipeline with Australian research.
Dr Jacques Servier founded Servier in France in 1954 and led his company to its established global presence today. Of the current 16,000 personnel in 140 countries, 2,500 are in research and development.
Servier is represented in Australia through its Melbourne based subsidiary, which has a 20-year history of productive partnership with Australian research organisations. The local operation has 200 staff, including 30 researchers in Servier's first non-European International Centre for Therapeutic Research (ICTR). "This Centre has participated in creating an extensive network in the academic, clinical and medical research community" says Patrick Tête, Chief Executive Officer of Servier Australia. "Over the years, research conducted in Australia has made a major contribution to the development of new products for global markets."
Servier's clinical trials have involved most major hospitals throughout Australia. Current partners include the Austin & Repatriation Medical Centre, the Baker Heart Research Institute in Melbourne, Sydney's George Institute for International Health and the Universities of Queensland and Melbourne.
Current and planned work includes discovery projects and pre-clinical and clinical studies in the Australian Government's National Health Priority Areas, such as cardiovascular disease, diabetes, osteoporosis, depression and schizophrenia.